Härnryd C, Bjerkenstedt L, Björk K, Gullberg B, Oxenstierna G, Sedvall G, Wiesel F A, Wik G, Aberg-Wistedt A
Acta Psychiatr Scand Suppl. 1984;311:7-30. doi: 10.1111/j.1600-0447.1984.tb06856.x.
To evaluate the clinical potential of sulpiride for the treatment of schizophrenic patients, a double-blind study was performed comparing fixed doses of sulpiride (800 mg daily) and chlorpromazine (400 mg daily). Twenty-five schizophrenic (RDC) patients participated in each treatment group. Antipsychotic effects were evaluated by CPRS and NOSIE ratings before and after 1, 2, 4 and 8 weeks of treatment. Interrater reliabilities for CPRS items and subscales were satisfactory. Treatment with sulpiride or chlorpromazine resulted in a significant reduction of psychotic morbidity as estimated by CPRS and global ratings. CPRS scores reflecting autism were significantly reduced in all ratings of sulpiride-treated patients, but only after four weeks in the chlorpromazine group. Total NOSIE scores indicated improvement in both treatment groups. A significant difference in favour of sulpiride was obtained for the NOSIE subscale "retardation". Extrapyramidal side effects occurred at a similar frequency in both treatment groups. Autonomic side effects occurred to a greater extent in chlorpromazine-treated patients. Lactation was reported only in four sulpiride-treated patients. Liver transaminase enzymes in serum were markedly elevated only in chlorpromazine-treated patients. The results indicate that sulpiride has a marked antipsychotic effect which is at least not inferior to that of chlorpromazine. A better effect on autistic components of behaviour was demonstrated for sulpiride. The results indicate a higher risk of lactation but a lower risk of anticholinergic side effects and liver toxicity for treatment with sulpiride than with chlorpromazine.
为评估舒必利治疗精神分裂症患者的临床潜力，进行了一项双盲研究，比较了固定剂量的舒必利（每日800毫克）和氯丙嗪（每日400毫克）。每个治疗组有25名精神分裂症（RDC）患者参与。在治疗1、2、4和8周前后，通过CPRS和NOSIE评分评估抗精神病作用。CPRS项目和分量表的评分者间信度令人满意。舒必利或氯丙嗪治疗使CPRS和整体评分所估计的精神病发病率显著降低。在舒必利治疗患者的所有评分中，反映孤独症的CPRS分数均显著降低，但氯丙嗪组仅在四周后出现这种情况。总的NOSIE分数表明两个治疗组均有改善。在NOSIE分量表“迟钝”方面，舒必利组有显著优势。两个治疗组锥体外系副作用的发生频率相似。自主神经副作用在氯丙嗪治疗的患者中出现的程度更大。仅在4名舒必利治疗的患者中报告有泌乳现象。仅在氯丙嗪治疗的患者中血清肝转氨酶明显升高。结果表明，舒必利具有显著的抗精神病作用，至少不低于氯丙嗪。舒必利对行为的孤独症成分有更好的疗效。结果表明，与氯丙嗪相比，舒必利治疗时泌乳风险较高，但抗胆碱能副作用和肝毒性风险较低。
